Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

FDA Approves Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

August 20th 2020

The FDA has approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.

Bevacizumab Biosimilar Aybintio Approved in Europe

August 20th 2020

The European Commission has granted a marketing authorization to Aybintio, a bevacizumab biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.

FDA Grants Fast Track Status to Paxalisib for Glioblastoma

August 20th 2020

The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.

Repotrectinib Elicits Encouraging Response Rates in ROS1- and NTRK-Driven Tumors

August 19th 2020

Treatment with repotrectinib resulted in favorable responses in patients with ROS1- or NTRK-driven tumors, regardless of prior treatment with TKIs, according to interim data from the phase 2 TRIDENT-1 trial.

Pembrolizumab/Chemo Combo Significantly Boosts Survival in Esophageal Cancer

August 19th 2020

Pembrolizumab in combination with chemotherapy significantly improved overall survival and progression-free survival in the frontline treatment of patients with locally advanced or metastatic esophageal cancer.

FDA Halts Phase 1 Trial With P-PSMA-101 in mCRPC Following Patient Death

August 18th 2020

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer

August 18th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

Experts Examine Emerging Approaches in Melanoma Management

August 18th 2020

A panel of experts discuss some of the encouraging data on emerging modalities in melanoma presented during the 2020 ASCO Virtual Scientific Program and share how they might apply that information to clinical practice.

FDA Grants Trilaciclib Priority Review for Small Cell Lung Cancer

August 17th 2020

The FDA has granted a priority review designation to a new drug application (NDA) for trilaciclib for the treatment of patients with small cell lung cancer (SCLC) who are being treated with chemotherapy.

Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors

August 13th 2020

The combination of dabrafenib and trametinib elicited favorable response rates in a mixed histology cohort of pretreated patients with solid tumors, lymphomas, and multiple myeloma whose tumors harbored a BRAF V600 mutation.

FDA Panel Supports Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD

August 13th 2020

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

Debio 1143 Significantly Boosts OS in High-Risk Head and Neck Cancer

August 13th 2020

Debio 1143 in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy was found to induce a statistically and clinically significant improvement in overall survival compared with CRT alone in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.

Phase 3 OVAL Trial With VB-111 in Platinum-Resistant Ovarian Cancer to Continue

August 12th 2020

The independent data safety monitoring committee has unanimously recommended that the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer continue as planned.

Nivolumab Plus Chemotherapy Shows Significant Survival Benefit in Gastric and Esophageal Cancers

August 11th 2020

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma

Adjuvant Nivolumab Significantly Improves DFS in Resected Esophageal or GEJ Cancer

August 11th 2020

Nivolumab, following neoadjuvant chemoradiation and complete surgical resection, resulted in a statistically significant improvement in disease-free survival in patients with resected esophageal or gastroesophageal junction cancer.

FDA Issues Complete Response Letter for Pedmark for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 11th 2020

The FDA has issued a complete response letter to Fennec Pharmaceuticals regarding its new drug application for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

Sequential Afatinib and Osimertinib Shows Continued OS Benefit in EGFR+ NSCLC

August 10th 2020

Treatment with afatinib followed by osimertinib resulted in a median overall survival benefit of almost 4 years in US patients with EGFR T790M–positive non–small cell lung cancer in the real-world setting.

CS1001 Plus Chemotherapy Shows Significant PFS Prolongation in Stage IV NSCLC

August 10th 2020

The anti–PD-L1 monoclonal antibody CS1001 in combination with platinum-based chemotherapy led to a significant improvement in progression-free survival when used as a frontline treatment for patients with stage IV squamous and nonsquamous non–small cell lung cancer.

Ensartinib Significantly Prolongs PFS Over Crizotinib in ALK+ NSCLC

August 8th 2020

Ensartinib showed a significant improvement in progression-free survival over crizotinib with a favorable safety profile in patients with ALK-positive non–small cell lung cancer.

FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 7th 2020

The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.